Viewing Study NCT02984995



Ignite Creation Date: 2024-05-06 @ 9:27 AM
Last Modification Date: 2024-10-26 @ 12:14 PM
Study NCT ID: NCT02984995
Status: COMPLETED
Last Update Posted: 2020-02-17
First Post: 2016-12-05

Brief Title: Phase 2 Study of Quizartinib in Participants With Acute Myeloid Leukemia AML FLT3 Internal Tandem Duplication FLT3ITD Mutation
Sponsor: Daiichi Sankyo Co Ltd
Organization: Daiichi Sankyo

Study Overview

Official Title: Phase 2 Open-label Single-arm Study of Quizartinib AC220 Monotherapy in Japanese Patients With FLT3-ITD Positive Refractory or Relapsed Acute Myeloid Leukemia
Status: COMPLETED
Status Verified Date: 2020-02
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: This is a Phase 2 multi-center open-label study to evaluate the efficacy safety and pharmacokinetics of quizartinib monotherapy in Japanese subjects with FLT3-ITD positive refractory or relapsed acute myeloid leukemia
Detailed Description: None

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: True
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: True
Is an FDA AA801 Violation?: None
Secondary IDs
Secondary ID Type Domain Link
JAPIC CTI-163441 OTHER JAPIC CTI None